Chuan He

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Rectify Pharmaceuticals LLC is a biotech company that is developing positive functional modulators (PFMs) to address the underlying cause of serious ABC transporter-mediated diseases. The company is based in Cambridge, MA and was founded by Jonathan Moore. The company's team includes Xiaobing Li as Chief Development Officer, Robert Hughes as Executive Vice President of Drug Discovery and Preclinical Development, and Leif-Ann Tuohey as Senior Vice President and Head of Business Development. The company has received $100 million in Series A financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund. The CEO is Rajesh Devraj, who is also a venture partner at Atlas Venture.

California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA.

BioDuro (Beijing) Co., Ltd. operates as a integrated drug discovery outsourcing company that provides integrated research and development services to biopharmaceutical clients. Its services range from medicinal chemistry to discovery biology, pharmacology, drug metabolism and pharmacokinetics (DMPK) and drug safety evaluation. The company was founded in 2006 and is headquartered in Beijing, China.

BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA.

BioDuro LLC provides research and development services for the life science industry. It offers services in the areas of chemistry, discovery biology, drug metabolism and pharmacokinetics and pharmacology, as well as integrated preclinical research and development. The company was founded by Masood K. Tayebi and John V. Oyler in 2005 and is headquartered in San Diego, CA.

USVP Management Co. LLC (US Venture Partners) is a venture capital firm founded in 1981 by Bill Bowes. The firm is headquartered in Menlo Park, California.

Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT.

Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada.

Eikon Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Hayward, CA.

Ribon Therapeutics, Inc. operates as a biotechnology company which focuses on developing therapeutics targeting monoADP-ribosylating PARPs for cancer. Its medicines are used for blocking cancer cells? fundamental survival mechanisms. The company was founded by W. Lee Kraus, Tim Mitchison and Paul Chang in 2015 and is headquartered in Lexington, MA.

Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA.

Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston.

Orbital Therapeutics, Inc. is a company based in Cambridge, MA that aims to enhance health by utilizing RNA-based medicines to treat human diseases in innovative ways. The company is building a platform that combines RNA technology delivery methods, data science, and automation to develop a portfolio of medicines focused on vaccines, immunomodulation, protein replacement, and regenerative medicine. The company was founded by Drew Weissman, John M. Maraganore, Kristina M. Burow, Ravindra Majeti, Giuseppe Ciaramella, Eugene W. Yeo, Howard Y. Chang, and Carol Suh, with Giuseppe Ciaramella serving as the CEO since incorporation.

BMS GmbH Beschickungssysteme Maschinen für Keramik und Umwelt is a German company that manufactures special purpose machinery. The private company is based in Goerlitz, Germany and was founded in 1994.

Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT.

Soilos, Inc. is a digital asset platform that provides a comprehensive crypto-as-a-service offering to leading banks, fintech institutions, and investment applications. The company is based in Valletta, MT, and has subsidiaries in the United States. The Maltese company simplifies the complex landscape of digital assets for its institutional clients with seamless price discovery and trade execution strategies at zero slippage and no hidden fees. Soilos is the largest, most reliable prime brokerage for the world's leading institutions and the first CFTC registered swap dealer. The company was founded by Raghuveer Yarlagadda and Prabhakar Reddy, and the CEO is Raghu Yarlagadda.

Part of Memorial Sloan Kettering Cancer Center, Tri-Institutional Therapeutics Discovery Institute, Inc. is an American New York-based company that encourages the Tri-Institutional community to advance their biological discoveries to preclinical studies. The company provides technical support for academic projects and offers a menu of services to translate research discoveries from bench to bedside. Tri-Institutional Therapeutics Discovery Institute achieves its mission by leveraging the infrastructure, staff, and intellectual capital of its academic and industry partners, as well as the generous support of philanthropists. The company was founded by David A. Scheinberg.

Cartography Biosciences, Inc. is a biotech company that specializes in developing tumor-selective therapeutics using a unique genomics and computational platform. The company is based in Foster City, CA. The company integrates data from proprietary sample sourcing relationships, a comprehensive reference atlas, and target identification algorithms to identify the cells of interest and the single or pairs of targets that are most specific to the intended target cells. Cartography Biosciences is unlocking the full potential of immunotherapy by discovering and developing therapeutics as precise as their targets. The company was founded by Ansuman Satpathy, Howard Y. Chang, Kevin Parker. Kevin Parker has been the CEO since incorporation.

Epinomics, Inc. provides decoding programming of genome to drive personalized medicine. The company was founded by Paul Giresi, Fergus Chan, Howard Y. Chang and Will Greenleaf and is headquartered in Menlo Park, CA.

Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation.

Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021.

Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA.